SAN ANTONIO (May 29, 2024) – SARS-CoV-2, the virus that causes COVID-19 disease, continues to evolve and evade current vaccine and therapeutic interventions. A consortium of scientists at Texas ...
Sanofi has developed a simpler way to create site-specific antibody-to-mannose-6-phosphate (M6P) conjugates that eliminates the need for enzyme remodeling. This more straightforward method makes M6P ...
Antibody-drug conjugates (ADCs) have been in development for decades, but only about a dozen have received FDA approval. Clearly, ADCs still have some major challenges. Yet they have done little to ...
It is essential that both primary and secondary bodies be selected to be in line with the needs of the intended application so that the application itself can provide the answers and to the researcher ...
Researchers have identified a promising new weapon against triple-negative breast cancer, one of the most aggressive forms of ...
IPA announces discovery of additional, neutralizing antibodies, developed against SARS-CoV-2, discovered using Ligand Pharmaceuticals' genetically engineered OmniRat® strains producing human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results